Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Sattler

Showing results (91-100 of 131) with videos related to

Pageof 14
Sort By:
British Journal of Haematology|July 17, 2019
Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignanciesEllen Weisberg, Chengcheng Meng, Abigail E Case, et al.
Leukemia|February 24, 2015
Pathological glycogenesis through glycogen synthase 1 and suppression of excessive AMP kinase activity in myeloid leukemia cellsHaymanti Bhanot, Mamatha M Reddy, Atsushi Nonami, et al.
Haematologica|June 18, 2026
Dual CDK2 and CDK4/6 inhibition suppresses Rb/E2F signaling and enhances anti-leukemic activity in acute myeloid leukemiaEllen Weisberg, Basudev Chowdhury, Swati Garg, et al.
Blood|January 25, 2008
The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenesGerlinde Wernig, Jeffrey R Gonneville, Brian J Crowley, et al.
Oncotarget|September 9, 2017
Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinaseEllen L Weisberg, Alexandre Puissant, Richard Stone, et al.
Cell Reports|June 15, 2022
YAP1 maintains active chromatin state in head and neck squamous cell carcinomas that promotes tumorigenesis through cooperation with BRD4Nana Chen, Gabriel Golczer, Subhoshree Ghose, et al.
Journal of Clinical Medicine|October 23, 2019
Phenotypic Switching of Naïve T Cells to Immune-Suppressive Treg-Like Cells by Mutant KRASArjun Kalvala, Pierre Wallet, Lu Yang, et al.
Biorxiv : the Preprint Server for Biology|September 26, 2025
YAP1 drives aggressive and therapy resistant state in melanoma through reprogramming the chromatin and regulating immune evasive programsNana Chen, Gracia Bonilla, Abdullah Ai Emran, et al.
Future Science OA|January 13, 2021
Co-stimulatory and co-inhibitory immune markers in solid tumors with <i>MET</i> alterationsKaren L Reckamp, Jasmine A McQuerry, Isa Mambetsariev, et al.
Oncogenesis|September 6, 2019
EPHA2 mutations with oncogenic characteristics in squamous cell lung cancer and malignant pleural mesotheliomaYi-Hung Carol Tan, Saumya Srivastava, Brian M Won, et al.
Pageof 14

Showing results (91-100 of 131) with videos related to

Sort By:
Pageof 14
British Journal of Haematology|July 17, 2019
Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignanciesEllen Weisberg, Chengcheng Meng, Abigail E Case, et al.
Leukemia|February 24, 2015
Pathological glycogenesis through glycogen synthase 1 and suppression of excessive AMP kinase activity in myeloid leukemia cellsHaymanti Bhanot, Mamatha M Reddy, Atsushi Nonami, et al.
Haematologica|June 18, 2026
Dual CDK2 and CDK4/6 inhibition suppresses Rb/E2F signaling and enhances anti-leukemic activity in acute myeloid leukemiaEllen Weisberg, Basudev Chowdhury, Swati Garg, et al.
Blood|January 25, 2008
The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenesGerlinde Wernig, Jeffrey R Gonneville, Brian J Crowley, et al.
Oncotarget|September 9, 2017
Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinaseEllen L Weisberg, Alexandre Puissant, Richard Stone, et al.
Cell Reports|June 15, 2022
YAP1 maintains active chromatin state in head and neck squamous cell carcinomas that promotes tumorigenesis through cooperation with BRD4Nana Chen, Gabriel Golczer, Subhoshree Ghose, et al.
Journal of Clinical Medicine|October 23, 2019
Phenotypic Switching of Naïve T Cells to Immune-Suppressive Treg-Like Cells by Mutant KRASArjun Kalvala, Pierre Wallet, Lu Yang, et al.
Biorxiv : the Preprint Server for Biology|September 26, 2025
YAP1 drives aggressive and therapy resistant state in melanoma through reprogramming the chromatin and regulating immune evasive programsNana Chen, Gracia Bonilla, Abdullah Ai Emran, et al.
Future Science OA|January 13, 2021
Co-stimulatory and co-inhibitory immune markers in solid tumors with <i>MET</i> alterationsKaren L Reckamp, Jasmine A McQuerry, Isa Mambetsariev, et al.
Oncogenesis|September 6, 2019
EPHA2 mutations with oncogenic characteristics in squamous cell lung cancer and malignant pleural mesotheliomaYi-Hung Carol Tan, Saumya Srivastava, Brian M Won, et al.
Pageof 14